IncellDx said recently that that it has signed an agreement with Singapore-based Biolidics to distribute its IncellDx bioINK PD-L1 CTC Core Kit. 

As part of the agreement, Biolidics will distribute the kit with Biolidics' ClearCell FX1 system. 

According to San Carlos, California-based IncellDx, the kit is pre-optimized to allow highly sensitive and specific quantification of protein or mRNA expression on CTCs at a single-cell-by-cell resolution for microfluidic chips. It added that the method minimizes clumping and aggregates of platelets and red blood cells while preserving RNA and DNA for downstream sequencing applications after preidentification of CTCs.

"We are very excited to expand our launch of our proprietary liquid biopsy reagent technology contained in our bioINK kits," IncellDx CEO Bruce Patterson said in a statement. "This agreement covers the first of many cancer-specific bioINK kits, including kits for breast cancer, lung cancer, urologic cancers, and sarcomas." 

Specific details of the deal were not disclosed. 

IncellDx previously partnered with Beckman Coulter Life Sciences in November to promote newly developed cancer assays that incorporate technology from each company.